Tech2Biotech

Independent, institutional-grade analysis across biotech, MedTech, and applied deep tech shaping capital, commercialization, regulation, and global dynamics

[Tech2Biotech @Tech2Biotech]

Both books are available in paperback form now.

China Biotech Out-Licensing: How Global Licensing Deals Actually Get Done. https://t.co/t313Jd8FK6

The China Biotech Deal The companion novel. Each chapter ties back to a key point in the guide. https://t.co/AfZYlh82Ga

[Tech2Biotech @Tech2Biotech]

Tech2Biotech #17 - MedTech's next venture returns will be built on equipment hospitals already own. #Medtech

https://t.co/UsZzeFxyhf

[Tech2Biotech @Tech2Biotech]

FDA published a 30 page paper on generative AI medical devices last month.

Everyone read it as a regulatory story.

It's a margin story.

Publication #16 out now. https://t.co/jTMgFkf77Q

#FDA #GenerativeAIMedicalDevices #MedTech #AIMedicalDevices #DigitalHealth #VentureCapital #RegulatoryAffairs

[Tech2Biotech @Tech2Biotech]

China Biotech Out-Licensing: Two New Books. One Transformative Market.
China Biotech Out-Licensing: How Global Licensing Deals Actually Get Done — the practitioner handbook. 19 chapters. 10 appendices. 40 footnotes. $39.99.
The China Biotech Deal — the companion novel. 18 chapters. 19 Framework Notes. $19.99.
Available now on Amazon Kindle and Gumroad. Free Kindle samples. Bundle both for $49.99.
Handbook: https://t.co/mHiE1lkVpq
Novel: https://t.co/cWfrmZmxgB

[Tech2Biotech @Tech2Biotech]

#ChinaBiotech #BiotechLicensing #OutLicensing #Pharma #Biopharma #BusinessDevelopment #LifeSciences #MedTech #DrugDevelopment #BiotechDeals #CrossBorderDeals #ChinaPharma #BiotechInvesting #Tech2Biotech

[Tech2Biotech @Tech2Biotech]

China Biotech Out-Licensing: Two New Books. One Transformative Market.
China Biotech Out-Licensing: How Global Licensing Deals Actually Get Done — the practitioner handbook. 19 chapters. 10 appendices. 40 footnotes. $39.99.
The China Biotech Deal — the companion novel. 18 chapters. 19 Framework Notes. $19.99.
Available now on Amazon Kindle and Gumroad. Free Kindle samples. Bundle both for $49.99.
Handbook: https://t.co/mHiE1lkVpq
Novel: https://t.co/cWfrmZmxgB

[Tech2Biotech @Tech2Biotech]

UPDATE: Both books are now available on Amazon Kindle as well.
China Biotech Out-Licensing: How Global Licensing Deals Actually Get Done — $39.99
https://t.co/mHiE1lkVpq
The China Biotech Deal — $19.99

Free samples available on both Kindle editions.
Still available on Gumroad individually and as a bundle option ($49.99 for both books):
#chinabiotech #biotech #biotechoutlicensing

[Tech2Biotech @Tech2Biotech]

UPDATE: Both books are now available on Amazon Kindle as well.
China Biotech Out-Licensing: How Global Licensing Deals Actually Get Done — $39.99
https://t.co/mHiE1lkVpq
The China Biotech Deal — $19.99
https://t.co/cWfrmZmxgB
Free samples available on both Kindle editions.
Still available on Gumroad individually and as a bundle option ($49.99 for both books): https://t.co/qBIWjiGUjw

[Tech2Biotech @Tech2Biotech]

My first book is available for purchase.

China Biotech Out-Licensing: How Global Licensing Deals Actually Get Done on @Gumroad https://t.co/UzdYqhEVl0

A practitioner handbook for structuring, diligencing, negotiating, and governing China biotech out-licensing deals. 19 chapters and 10 working appendices.

Written for BD executives, investors, attorneys, corporate development teams, Chinese founders, and the academics and researchers studying the deals reshaping global biotech and pharma.

$39.99 → https://t.co/bqEn2UA5xg

[Tech2Biotech @Tech2Biotech]

My companion narrative to China Biotech Out-Licensing is available as well.

The China Biotech Deal

Two careers. One deal. A market that changed overnight when Summit Therapeutics paid $500 million for a molecule most Western executives had never heard of.

18 chapters. 19 Framework Notes linking each chapter to the practitioner handbook.Fiction grounded in real deals, real regulations, and real stakes.
$19.99 → https://t.co/I585MdmEmZ

[Tech2Biotech @Tech2Biotech]

#biotech #pharma #licensing #ChinaBiotech #businessdevelopment #lifesciences #MedTech #outlicensing #biotechinvesting #drugdevelopment

[Tech2Biotech @Tech2Biotech]

BIO International 2026 wraps tomorrow in San Diego.
Here's what the convention agenda reveals about where this industry is actually heading.
https://t.co/Gah4ixqqTC

[Tech2Biotech @Tech2Biotech]

The Manufacturing Paradox: Why the GLP-1 Revolution Is Creating a $200B+ Infrastructure Arms Race—and What It Means for the Next Decade of Biotech Value Creation https://t.co/W1wkMSbDKt #GLP1 #biotech #pharma #manufacturing

[Tech2Biotech @Tech2Biotech]

Publication # 11
The Pharma R&D Vacuum: Why Big Tech, Not Big Pharma, Will Buy the Next Generation of Biotech
https://t.co/xDJ1WdLbZh

[Tech2Biotech @Tech2Biotech]

Tech2Biotech https://t.co/VvgsTP3CvQ via @YouTube

[Tech2Biotech @Tech2Biotech]

Tech2Biotech Publication #10 is live: The China Out-Licensing Structure Test.
https://t.co/8dB9eBC3GT

[Tech2Biotech @Tech2Biotech]

Publication #9 is available:
https://t.co/UHYGGcp0C4

[Tech2Biotech @Tech2Biotech]

Publication #8
https://t.co/UN9LZdxMof

[Tech2Biotech @Tech2Biotech]

Rare disease biotech is not just slowing. It is resetting.

FDA expectations in late stage rare disease have become harder to predict, even after prior alignment. That shift is starting to show up in capital behavior.

Executive video brief and analysis: https://t.co/T8BfrUBlgo

[Tech2Biotech @Tech2Biotech]

China Is Becoming the Biotech Pricing Signal | Tech2Biotech Special Report
https://t.co/ExecnMAT7h